Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yazan Alsayed

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
European Journal of Haematology|June 25, 2008
Proteomics analysis in post-transplant lymphoproliferative disordersYazan Alsayed, Xavier Leleu, Alexey Leontovich, et al.
Cancer|October 15, 2010
International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocolsSarah Waheed, John D Shaughnessy, Frits van Rhee, et al.
Blood|February 4, 2010
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenanceBijay Nair, Frits van Rhee, John D Shaughnessy, et al.
Cancer|May 13, 2008
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myelomaBart Barlogie, Elias Anaissie, Jeffrey Haessler, et al.
Blood|May 27, 2010
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyFrits van Rhee, Jackie Szymonifka, Elias Anaissie, et al.
Blood|June 12, 2009
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocolsAntje Hoering, John Crowley, John D Shaughnessy, et al.
British Journal of Haematology|August 26, 2009
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3John D Shaughnessy, Yiming Zhou, Jeff Haessler, et al.
Haematologica|June 13, 2012
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agentsSaad Z Usmani, Christoph Heuck, Alan Mitchell, et al.
Blood|April 10, 2007
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisFrits van Rhee, Vanessa Bolejack, Klaus Hollmig, et al.
Blood|April 25, 2009
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survivalBijay Nair, John D Shaughnessy, Yiming Zhou, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
European Journal of Haematology|June 25, 2008
Proteomics analysis in post-transplant lymphoproliferative disordersYazan Alsayed, Xavier Leleu, Alexey Leontovich, et al.
Cancer|October 15, 2010
International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocolsSarah Waheed, John D Shaughnessy, Frits van Rhee, et al.
Blood|February 4, 2010
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenanceBijay Nair, Frits van Rhee, John D Shaughnessy, et al.
Cancer|May 13, 2008
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myelomaBart Barlogie, Elias Anaissie, Jeffrey Haessler, et al.
Blood|May 27, 2010
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyFrits van Rhee, Jackie Szymonifka, Elias Anaissie, et al.
Blood|June 12, 2009
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocolsAntje Hoering, John Crowley, John D Shaughnessy, et al.
British Journal of Haematology|August 26, 2009
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3John D Shaughnessy, Yiming Zhou, Jeff Haessler, et al.
Haematologica|June 13, 2012
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agentsSaad Z Usmani, Christoph Heuck, Alan Mitchell, et al.
Blood|April 10, 2007
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisFrits van Rhee, Vanessa Bolejack, Klaus Hollmig, et al.
Blood|April 25, 2009
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survivalBijay Nair, John D Shaughnessy, Yiming Zhou, et al.
Pageof 3